GET DAILY SIGNALSAlumis Inc. (ALMU) Falls 42% in 30 Days After Lupus Trial Miss: Key Factors for Investors
Key Takeaways
- Alumis Inc. (ALMU) shares have fallen roughly 42% over the last 30 days, declining from about $12.36 to around $7.19.
- The move extends a sell-off triggered by the Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus (SLE), which missed its primary and secondary endpoints in the overall patient population.
- The broader quarterly trend remains sharply negative, with shares falling more than 50% as investors reassessed the company's lupus program.
- Alumis remains on track to file a New Drug Application (NDA) for envudeucitinib in moderate-to-severe plaque psoriasis in the fourth quarter of 2026.
- Analyst reactions to the lupus setback were mixed, with several firms lowering price targets and at least two issuing downgrades.
- The stock now trades well below its 52-week high, reflecting renewed focus on financing, dilution, and regulatory-execution risk.
- For additional data, explore Alumis's Price Targets, Earnings, and Forecast pages to see analyst expectations and forward-looking metrics.
- For data-driven trading ideas, explore Trending AI Robots to see curated, top-performing automated strategies.
Alumis Inc. (ALMU) Company Background and Pipeline Focus
Alumis Inc. is a late-stage biopharmaceutical company headquartered in South San Francisco, California, focused on developing next-generation oral therapies for immune-mediated diseases. The company's lead asset, envudeucitinib (formerly ESK-001), is an oral, allosteric tyrosine kinase 2 (TYK2) inhibitor being developed for moderate-to-severe plaque psoriasis and systemic lupus erythematosus, among other interferon-driven conditions.
Alumis's pipeline also includes A-005, a central nervous system-penetrant TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases, and lonigutamab, a subcutaneous anti-IGF-1R antibody for thyroid eye disease acquired through the company's 2025 merger with ACELYRIN. The company generates limited revenue, primarily from a collaboration with Kaken Pharmaceutical, and investors follow ALMU primarily for its clinical data catalysts and the commercial potential of its TYK2 franchise.
ALMU Stock Price Performance: Recent 30 Days and Quarterly View
Over the last 30 days, ALMU has fallen from a closing price of approximately $12.36 to about $7.19, a decline of roughly 42%. The downward move was persistent rather than driven by a single day, with shares grinding lower through October despite periodic rebounds. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The quarterly picture is similarly negative. Shares entered early August trading near $17 and declined more than 55% through late October. The defining event of the quarter was the September 1 clinical readout, when ALMU plunged roughly 54% in a single session, from about $21.81 to $9.47, following the lupus trial miss. Although the stock stabilized briefly and posted a modest bounce on favorable psoriasis data in early October, it has continued to trend lower toward the $7 level.
What Drove the Recent Decline in ALMU Shares
The dominant catalyst remains the September Phase 2b LUMUS trial, in which envudeucitinib failed to meet its primary and secondary endpoints across the overall study population of 408 patients with moderate-to-severe SLE. Although the company highlighted robust responses in a prespecified subgroup of patients with a high interferon gene signature (IFNGS-high), the broader miss forced investors to reprice the lupus opportunity and left the psoriasis program as the primary near-term value driver.
In early October, Alumis announced new Phase 3 ONWARD data showing that envudeucitinib delivered 54% complete skin clearance (PASI 100) at Week 48 in plaque psoriasis, with durable improvements in scalp disease, itch, and quality of life. While the data reinforced the psoriasis case and the company's Q4 2026 NDA timeline, the market reaction was muted, reflecting caution around financing, dilution, and competitive positioning against established TYK2 therapies.
Quarterly Drivers and Analyst Responses
The quarter's broader narrative has been defined by a sharp reduction in the company's perceived pipeline breadth. Before the September readout, analysts broadly attributed meaningful value to the lupus indication; after the miss, several firms removed or sharply discounted that program from their models.
Following the data, Morgan Stanley lowered its price target from $39 to $29 while maintaining an Overweight rating, Wells Fargo cut its target from $51 to $25, and Oppenheimer reduced its target from $55 to $37. Guggenheim downgraded the stock to Neutral from Buy, and H.C. Wainwright moved to a Neutral rating. This mixed-to-negative analyst response, combined with persistent cash burn and the absence of product revenue, contributed to sustained selling pressure throughout the period.
ALMU Stock Forecast: Catalysts to Monitor
The most important near-term catalyst is Alumis's planned NDA submission for envudeucitinib in moderate-to-severe plaque psoriasis, expected in the fourth quarter of 2026. Investors will also watch the company's regulatory engagement with the FDA regarding Phase 3 development in a biomarker-defined SLE population, as well as any updates on cutaneous lupus erythematosus and Sjögren's disease.
Additional factors include the company's cash runway, which management has indicated extends into the fourth quarter of 2027, and the potential for further financing or dilution. Competitive dynamics also matter, particularly differentiation against Bristol Myers Squibb's Sotyktu and Johnson & Johnson's Icotyde in the oral psoriasis market. Macroeconomic and sector conditions affecting biotech valuations, including interest rates and risk appetite for pre-revenue clinical-stage companies, remain relevant to sentiment. From what I see, these elements will likely shape near-term moves.
Using Tickeron Tools in My Analysis
In my own research process, I frequently review Tickeron’s AI Trend Prediction Engine to gauge potential momentum shifts in names like ALMU alongside traditional fundamentals. The platform’s data-driven signals help provide additional context when evaluating clinical-stage biotechs amid volatile news flow.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
ALMU's RSI Oscillator climbs out of oversold territory
The RSI Oscillator for ALMU moved out of oversold territory on October 27, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 14 similar instances when the indicator left oversold territory. In 14 of the 14 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 36 of 39 cases where ALMU's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for ALMU just turned positive on October 29, 2026. Looking at past instances where ALMU's MACD turned positive, the stock continued to rise in 36 of 44 cases over the following month. The odds of a continued upward trend are 82%.
Following a +3.74% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALMU advanced for three days, in 112 of 136 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
ALMU may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALMU as a result. In 69 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALMU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for ALMU entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.721) is normal, around the industry mean (6.493). P/E Ratio (-15.462) is within average values for comparable stocks, (21.736). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.761). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (53.191) is also within normal values, averaging (45.794).
The Tickeron Price Growth Rating for this company is 92 (best 1 - 100 worst), indicating slightly worse than average price growth. ALMU’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALMU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 75, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Semiconductors
Advertisement